Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: Relationship to glycemia

被引:91
作者
Deane, Adam M. [1 ,2 ,3 ]
Chapman, Marianne J. [1 ,2 ,3 ]
Fraser, Robert J. L. [3 ,4 ]
Summers, Matthew J. [5 ]
Zaknic, Antony V. [5 ]
Storey, James P. [1 ,6 ]
Jones, Karen L. [3 ,4 ]
Rayner, Christopher K. [3 ,4 ]
Horowitz, Michael [3 ,4 ]
机构
[1] Royal Adelaide Hosp, Intens Care Unit, Adelaide, SA 5000, Australia
[2] Univ Adelaide, Discipline Anaesthesia & Intens Care, Adelaide, SA, Australia
[3] Australia Ctr Clin Res Excellence Nutr Physiol &, Natl Hlth & Med Res Council, Adelaide, SA, Australia
[4] Univ Adelaide, Discipline Med, Adelaide, SA, Australia
[5] Royal Adelaide Hosp, Dept Gastroenterol, Adelaide, SA 5000, Australia
[6] Leeds Gen Infirm, Dept Acute Med, Leeds, W Yorkshire, England
基金
英国医学研究理事会;
关键词
glucagon-like peptide 1; blood glucose; hyperglycemia; critical illness; gastric emptying; enteral nutrition; TYPE-2; DIABETES-MELLITUS; HEALTHY-SUBJECTS; BLOOD-GLUCOSE; INHIBITORY POLYPEPTIDE; POSTPRANDIAL GLYCEMIA; CRITICAL ILLNESS; INSULIN-SECRETION; MEAL DISTRIBUTION; HUMANS; INCRETIN;
D O I
10.1097/CCM.0b013e3181d9d87a
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: To determine the acute effects of exogenous glucagon-like peptide-1 on gastric emptying, glucose absorption, glycemia, plasma insulin, and glucagon in critically ill patients. Design: Randomized, double-blind, crossover study. Setting: Intensive care unit. Subjects: Twenty-five mechanically ventilated patients, without known diabetes, studied on consecutive days. Interventions: Intravenous glucagon-like peptide-1 (1.2 pmol/kg/ min) or placebo was infused between -30 and 330 mins. At 0 min, 100 mL liquid nutrient (1 kcal/mL) including 100 mu g of (13)C-octanoic acid and 3 grams of 3-0-methyl-glucose was administered. Measurements and Main Results: Blood glucose, serum 3-0-methyl-glucose (as an index of glucose absorption), insulin and glucagon concentrations, as well as exhaled (13)CO(2) were measured. The gastric emptying coefficient was calculated to quantify gastric emptying. Data are presented as mean (SD). There was a nonsignificant trend for glucagon-like peptide-1 to slow gastric emptying (gastric emptying coefficient) (glucagon-like peptide-1, 2.45 [0.93] vs. placebo, 2.75 [0.83]; p = .09). In 11 of the 25 patients, gastric emptying was delayed during placebo infusion and glucagon-like peptide-1 had no detectable effect on gastric emptying in this group (1.92 [0.82] vs. 1.90 [0.68]; p = .96). In contrast, in patients who had normal gastric emptying during placebo, glucagon-like peptide-1 slowed gastric emptying substantially (2.86 [0.58] vs. 3.41 [0.37]; p = .006). Glucagon-like peptide-1 markedly reduced the rate of glucose absorption (3-0-methyl-glucose area under the curve(0-330), 37 [35] vs. 76 [51] mmol/L/min; p < .001), decreased preprandial glucagon (at 0 min change in glucagon, -15 [15] vs. -3 [14] pmol/L; p < .001), increased the insulin/glucose ratio throughout the infusion (area under the curve(-30-330), 1374 [814] vs. 1172 [649] mU/mmol/min; p = .041), and attenuated the glycemic response to the meal (glucose area under the curve(0-330), 2071 [353] vs. 2419 [594] mmol/L/min; p = .001). Conclusions: Exogenous glucagon-like peptide-1 lowers post-prandial glycemia in the critically ill. This may occur, at least in part, by slowing gastric emptying when the latter is normal but not when it is delayed. (Crit Care Med 2010; 38:1261-1269)
引用
收藏
页码:1261 / 1269
页数:9
相关论文
共 45 条
  • [21] The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans
    Meier, JJ
    Gethmann, A
    Nauck, MA
    Götze, O
    Schmitz, F
    Deacon, CF
    Gallwitz, B
    Schmidt, WE
    Holst, JJ
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2006, 290 (06): : E1118 - E1123
  • [22] Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects
    Meier, JJ
    Kemmeries, G
    Holst, JJ
    Nauck, MA
    [J]. DIABETES, 2005, 54 (07) : 2212 - 2218
  • [23] Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes
    Meier, JJ
    Weyhe, D
    Michaely, M
    Senkal, M
    Zumtobel, V
    Nauck, MA
    Hoist, JJ
    Schmidt, WE
    Gallwitz, B
    [J]. CRITICAL CARE MEDICINE, 2004, 32 (03) : 848 - 851
  • [24] Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects
    Meier, JJ
    Nauck, MA
    Kranz, D
    Holst, JJ
    Deacon, CF
    Gaeckler, D
    Schmidt, WE
    Gallwitz, B
    [J]. DIABETES, 2004, 53 (03) : 654 - 662
  • [25] Gastric inhibitory polypeptide does not inhibit gastric emptying in humans
    Meier, JJ
    Goetze, O
    Anstipp, J
    Hagemann, D
    Holst, JJ
    Schmidt, WE
    Gallwitz, B
    Nauck, MA
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2004, 286 (04): : E621 - E625
  • [26] Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes
    Meier, JJ
    Gallwitz, B
    Salmen, S
    Goetze, O
    Holst, JJ
    Schmidt, WE
    Nauck, MA
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (06) : 2719 - 2725
  • [27] Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes
    Muessig, Karsten
    Oencu, Arzu
    Lindauer, Philipp
    Heininger, Alexandra
    Aebert, Hermann
    Unertl, Klaus
    Ziemer, Gerhard
    Haering, Hans-Ulrich
    Gallwitz, Baptist
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2008, 102 (05) : 646 - 647
  • [28] Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1
    Nauck, MA
    Walberg, J
    Vethacke, A
    El-Ouaghlidi, A
    Senkal, M
    Holst, JJ
    Gallwitz, JB
    Schmidt, WE
    Schmiegel, W
    [J]. REGULATORY PEPTIDES, 2004, 118 (1-2) : 89 - 97
  • [29] Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers
    Nauck, MA
    Heimesaat, MM
    Behle, K
    Holst, JJ
    Nauck, MS
    Ritzel, R
    Hüfner, M
    Schmiegel, WH
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (03) : 1239 - 1246
  • [30] PRESERVED INCRETIN ACTIVITY OF GLUCAGON-LIKE PEPTIDE-1 [7-36 AMIDE] BUT NOT OF SYNTHETIC HUMAN GASTRIC-INHIBITORY POLYPEPTIDE IN PATIENTS WITH TYPE-2 DIABETES-MELLITUS
    NAUCK, MA
    HEIMESAAT, MM
    ORSKOV, C
    HOLST, JJ
    EBERT, R
    CREUTZFELDT, W
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (01) : 301 - 307